Literature DB >> 24998451

Genomic profiling of inflammatory breast cancer: a review.

François Bertucci1, Pascal Finetti2, Peter Vermeulen3, Peter Van Dam4, Luc Dirix3, Daniel Birnbaum2, Patrice Viens5, Steven Van Laere6.   

Abstract

Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer. Despite efforts in the past decade to delineate the molecular biology of IBC by applying high-throughput molecular profiling technologies to clinical samples, IBC remains insufficiently characterized. The reasons for that include limited sizes of the study population, heterogeneity with respect to the composition of the IBC and non-IBC control groups and technological differences across studies. In 2008, the World IBC Consortium was founded to foster collaboration between research groups focusing on IBC. One of the initial projects was to redefine the molecular profile of IBC using an unprecedented number of samples and search for gene signatures associated with survival and response to neo-adjuvant chemotherapy. Here, we provide an overview of all the molecular profiling studies that have been performed on IBC clinical samples to date.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA microarrays; Genome profiling; Inflammatory breast cancer

Mesh:

Substances:

Year:  2014        PMID: 24998451     DOI: 10.1016/j.breast.2014.06.008

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  26 in total

1.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

2.  An unexpected diagnosis of breast malignancy.

Authors:  T Richardson; F Cottier
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

3.  PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.

Authors:  Anna R Michmerhuizen; Andrea M Pesch; Leah Moubadder; Benjamin C Chandler; Kari Wilder-Romans; Meleah Cameron; Eric Olsen; Dafydd G Thomas; Amanda Zhang; Nicole Hirsh; Cassandra L Ritter; Meilan Liu; Shyam Nyati; Lori J Pierce; Reshma Jagsi; Corey Speers
Journal:  Mol Cancer Ther       Date:  2019-08-14       Impact factor: 6.261

4.  Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Authors:  Komal Jhaveri; Eleonora Teplinsky; Deborah Silvera; Amanda Valeta-Magara; Rezina Arju; Shah Giashuddin; Yasmeen Sarfraz; Melissa Alexander; Farbod Darvishian; Paul H Levine; Salman Hashmi; Ladan Zolfaghari; Heather J Hoffman; Baljit Singh; Judith D Goldberg; Tsivia Hochman; Silvia Formenti; Francisco J Esteva; Meena S Moran; Robert J Schneider
Journal:  Clin Breast Cancer       Date:  2015-12-01       Impact factor: 3.225

5.  Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Authors:  François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

6.  Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.

Authors:  Olivia K Provance; Eric S Geanes; Asona J Lui; Anuradha Roy; Sean M Holloran; Sumedha Gunewardena; Christy R Hagan; Scott Weir; Joan Lewis-Wambi
Journal:  Cancer Lett       Date:  2021-05-20       Impact factor: 9.756

7.  PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Authors:  François Bertucci; Pascal Finetti; Cécile Colpaert; Emilie Mamessier; Maxime Parizel; Luc Dirix; Patrice Viens; Daniel Birnbaum; Steven van Laere
Journal:  Oncotarget       Date:  2015-05-30

8.  Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.

Authors:  Andrea Remo; Ines Simeone; Massimo Pancione; Pietro Parcesepe; Pascal Finetti; Luigi Cerulo; Halima Bensmail; Daniel Birnbaum; Steven J Van Laere; Vittorio Colantuoni; Franco Bonetti; François Bertucci; Erminia Manfrin; Michele Ceccarelli
Journal:  J Transl Med       Date:  2015-05-01       Impact factor: 5.531

9.  Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.

Authors:  Joshua Ogony; Hye Joung Choi; Asona Lui; Massimo Cristofanilli; Joan Lewis-Wambi
Journal:  Breast Cancer Res       Date:  2016-02-20       Impact factor: 6.466

10.  HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Authors:  Preeti Putcha; Jiyang Yu; Ruth Rodriguez-Barrueco; Laura Saucedo-Cuevas; Patricia Villagrasa; Eva Murga-Penas; Steven N Quayle; Min Yang; Veronica Castro; David Llobet-Navas; Daniel Birnbaum; Pascal Finetti; Wendy A Woodward; François Bertucci; Mary L Alpaugh; Andrea Califano; Jose Silva
Journal:  Breast Cancer Res       Date:  2015-12-08       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.